Wartość oznaczania stężeń antygenu nowotworowego Ca 125 i kopeptyny w monitorowaniu terapii chorych z zaawansowaną niewydolnością serca

Woźniak-Wiśniewska, Anita; Błażejewski, Jan; Bujak, Robert; Wołowiec, Łukasz; Rogowicz, Daniel; Sinkiewicz, Włądysław

doi:10.5603/fc.2017.0103

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These statistics show the great importance of precise risk stratification enabling early identification of subgroups of patients with the worst prognosis in order to quickly implement optimal treatment methods. Due to the important role of markers in HF [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ] and the need to discover new ones, we decided to evaluate the clinical usefulness of measuring plasma catestatin (CST) in patients with HFrEF as a predictor of unplanned hospitalization and all-cause death independently and as a composite endpoint at a two-year follow-up.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Wołowiec,

Banach,

Budzyński

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

The primary objective of the study was to evaluate the prognostic value of measuring plasma catestatin (CST) concentration in patients with heart failure with reduced ejection fraction (HFrEF) as a predictor of unplanned hospitalization and all-cause death independently and as a composite endpoint at 2-year follow-up. The study group includes 122 hospitalized Caucasian patients in NYHA classes II to IV. Patients who died during the 24-month follow-up period (n = 44; 36%) were significantly older on the day of enrollment, were more likely to be in a higher NYHA class, had lower TAPSE, hemoglobin concentration, hematocrit, and platelet count, higher concentrations of CST, NT-proBNP, troponin T, creatinine, and glucose, and higher red cell distribution width value and leukocyte and neutrocyte count than patients who survived the follow-up period. Plasma catestatin concentration increased with NYHA class (R = 0.58; p <0.001) and correlated significantly with blood NT-proBNP concentration (R = 0.44; p <0.001). We showed that higher plasma catestatin concentration increased the risk of all-cause death by more than five times. Plasma CST concentration is a valuable prognostic parameter in predicting death from all causes and unplanned hospitalization in patients with HFrEF.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Wołowiec,

Banach,

Budzyński

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up

Wołowiec,

Rogowicz,

Budzyński

et al. 2024

Annals of Medicine

Self Cite

View full text Add to dashboard Cite

Background This is the first study to examine the clinical utility of measuring plasma secretoneurin (SN) levels in patients with heart failure with reduced ejection fraction (HFrEF), as a predictor of unplanned hospitalization, and all-cause mortality independently, and as a composite endpoint at one-year follow-up. Methods The study group includes 124 caucasian patients in New York Heart Association (NYHA) classes II to IV. Plasma SN concentrations were statistically analyzed in relation to sex, age, BMI, etiology of HFrEF, pharmacotherapy, clinical, laboratory and echocardiographic parameters. Samples were collected within 24 h of admission to the hospital. Key results In the 12-month follow-up, high SN levels were noted for all three endpoints. Conclusions SN positively correlates with HF severity measured by NYHA classes and proves to be a useful prognostic parameter in predicting unplanned hospitalizations and all-cause mortality among patients with HFrEF. Patients with high SN levels may benefit from systematic follow-up and may be candidates for more aggressive treatment.

show abstract

Wartość oznaczania stężeń antygenu nowotworowego Ca 125 i kopeptyny w monitorowaniu terapii chorych z zaawansowaną niewydolnością serca

Cited by 2 publications

References 24 publications

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up

Contact Info

Product

Resources

About